| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 4, 2026 | Trump and Kennedy’s health industry deals haven’t been enforced and are at risk of vanishing | Getting your Trinity Audio player ready...
By Stephanie Armour, KFF Health News
In the thick of his competitive reelection race in Michigan, Republican Rep. Tom Barrett joined Health and Human Services Secretary Robert F. Kennedy Jr. at a s... |
| Jul 19, 2026 | Copay assistance is meant to defray patient drug costs. Some insurers keep it instead | Getting your Trinity Audio player ready...
By Daniel Chang, KFF Health News
For 16 years, Larry Gruber, a fitness coach from Wilton Manors, Florida, received a coupon card to help him pay for a psoriatic arthritis medication he needs that c... |
| Jul 7, 2026 | Colorado can’t cap price of arthritis drug Enbrel, federal judge rules | Getting your Trinity Audio player ready...
Colorado can’t cap the price of arthritis medication Enbrel while a lawsuit challenging the state’s drug affordability board’s action plays out, a federal judge ruled last week.
In 2024, the Colora... |
| Apr 7, 2026 | Corporate Vision and Trade Confrontation: The Shifting U.S. Economic Narrative | Motorola Solutions CEO Greg Brown earns top honors, lauded for transforming the company into a global public safety and security technology leader. His strategic vision and operational prowess drove exceptional growth and innovation. Meanwh... |
| Apr 2, 2026 | Diabetes advocates cross their fingers as a bipartisan bill revives efforts to lower insulin costs | Getting your Trinity Audio player ready...
By ALI SWENSON
NEW YORK (AP) — Two-year-old Bain Brandon has Type 1 diabetes and needs insulin to live. But even with health insurance, the price tag isn’t cheap. Related Articles
Trump has private... |
| Apr 2, 2026 | Trump unveils 100% tariff on some patented drugs on ‘Liberation Day’ anniversary | Getting your Trinity Audio player ready...
By WYATTE GRANTHAM-PHILIPS, AP Business Writer
NEW YORK (AP) — President Donald Trump signed an executive order Thursday that could slap long-threatened pharmaceutical tariffs of up to 100% on some... |
| Mar 24, 2026 | HKeyBio Launches HKEY-NHP-onChip™ 1.1: World's First NHP In Vitro Model for Autoimmune and Allergic Diseases | The integrated organ-on-chip platform offers 10–100x cost efficiency and 80% reduction in animal use, bridging the gap between preclinical NHP research and human clinical success.
SUZHOU, China, SAN FRANCISCO and BOSTON, March 24, 2026 /PRN... |
| Jan 27, 2026 | Trump administration announces 15 new drugs for Medicare price negotiation program | Getting your Trinity Audio player ready...
By ALI SWENSON
NEW YORK (AP) — Drugs that treat Type 2 diabetes, HIV and arthritis are among 15 new medications chosen for a Medicare drug price negotiation program that allows the federal governme... |
| Dec 20, 2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| Dec 19, 2025 | Nine of the largest pharma companies ink deals with Trump to lower drug prices | Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation’s drug prices to cheaper ones abroad.
Pfizer, ... |
| Sep 10, 2025 | Trump’s plan for a drug advertising crackdown faces many hurdles | By MATTHEW PERRONE
WASHINGTON (AP) — Health Secretary Robert F. Kennedy Jr. and other administration officials are vowing a crackdown on deceptive drug ads, but the effort is likely to face multiple headwinds, including pushback from indust... |
| Aug 14, 2025 | Trump Threatens Bayh‑Dole March‑In To Punish Harvard—After Refusing It For COVID | For years we’ve talked about the serious problems of the Bayh-Dole Act, which encouraged universities to patent every damn idea that anyone associated with the university came up with in the hopes of “commercializing” it. In practice this h... |
| Aug 6, 2025 | US to initially impose 'small tariff' on pharma imports, Trump says | WASHINGTON: President Donald Trump said on Tuesday (Aug 5) that the United States would initially impose a "small tariff" on pharmaceutical imports before raising it to 150 per cent within 18 months and eventually to 250 per cent,... |
| Aug 5, 2025 | US to initially impose 'small tariff' on pharma imports, Trump says | US to initially impose 'small tariff' on pharma imports, Trump says
By Patrick Wingrove and Andrea ShalalAugust 5, 20254:09 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
U.S. President Donald ... |
| Jul 11, 2025 | Trump’s 200% tariff threat leaves pharma firms scrambling with scenario planning | U.S. President Donald Trump warned again this week that long-awaited industry-wide tariffs would be announced “very soon.”
That levy, he said, could be up to 200% and may hit in 12 to 18 months.
Even with a delay, such a rate will have a de... |
| Jul 9, 2025 | Trump says pharmaceutical tariffs could reach 200% | WASHINGTON: US President Donald Trump on Tuesday (Jul 8) said he plans to announce tariffs on imported pharmaceuticals, which could reach 200 per cent, but he would give drugmakers about one year "to get their act together".
"... |
| Jul 8, 2025 | Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’ | President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. “very soon.”
But he suggested that those levies would not go into effect immediately, saying he will “give people about a year, year an... |
| May 24, 2025 | Pharmacists stockpile most common drugs on chance of targeted Trump tariffs | Squeezed by insurers and middlemen, independent pharmacists such as Jolley find themselves on the front lines of a tariff storm. Nearly everyone down the line — drugmakers, pharmacies, wholesalers, and middlemen — opposes most tariffs.
Slas... |
| May 13, 2025 | Trump’s Drug Price Plan: A Bold Move or a Pipe Dream? | In a bold stroke, President Donald Trump has revived a controversial policy aimed at slashing U.S. drug prices. The plan, known as the “most favored nation” policy, seeks to tie American drug prices to those in other developed countries, wh... |
| May 13, 2025 | The Price of Health: Trump’s Bold Move Against Drug Costs | In a bold stroke, President Donald Trump has taken aim at the soaring prices of prescription drugs in the United States. His recent executive order targets weight-loss medications, specifically the popular drugs Wegovy and Zepbound. The goa... |
| May 13, 2025 | Trump executive order demands pharma industry price cuts | Trump executive order demands pharma industry price cuts
By Steve Holland, Michael Erman and Patrick WingroveMay 13, 202512:49 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
SummaryCompanies
Tr... |
| May 12, 2025 | Trump signs order aiming to cut some U.S. drug prices to match lower ones abroad | President Donald Trump revived a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Trump signed an executive order including several different actions... |
| Apr 22, 2025 | Trump looking at cutting US drug prices to international levels, sources say | Trump looking at cutting US drug prices to international levels, sources say
By Patrick WingroveApril 22, 20251:59 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Item 1 of 2 Illustration photo ... |
| Feb 5, 2025 | Health | Colorado bill would bar drugmakers from limiting discount program that subsidizes safety-net hospitals | Drug companies have pushed back and refused to sell their products at the 340B discount to those “contract pharmacies.” But a new bill in the state legislature would forbid drugmakers from setting those kinds of limitations.
Senate Bill 71 ... |
| 2025 | Health | How a duty to spend wisely on worker benefits could loosen PBMs’ grip on drug prices | In recent years, the opaque business practices of PBMs have drawn fire. The Federal Trade Commission is conducting a lengthy investigation of the three biggest companies and sued them in September, accusing the firms of driving up insulin p... |
| Dec 5, 2024 | The Unraveling of COVID-19 Narratives: A Deep Dive into the Truth | The COVID-19 pandemic reshaped the world. It turned everyday life upside down. Masks became symbols of safety, while lockdowns felt like a necessary evil. But as time passed, questions arose. A recent report from the U.S. House of Represent... |
| Dec 5, 2024 | Former CSL CEO Paul Perreault appointed strategic adviser to Microbio | Establishing sepsis diagnostic InfectID™ as the new standard of care
BRISBANE, Australia, Dec. 5, 2024 /PRNewswire/ -- Microbio Ltd, the Australian pathogen diagnostics company specialising in innovative molecular diagnostic solutions, has ... |
| Sep 20, 2024 | Challenge to US drug price negotiation program revived by appeals court | Boards, Policy & RegulationHealth Insurance
Regulatory
Lawsuits
Government Health Policy
Challenge to US drug price negotiation program revived by appeals court
By Brendan PiersonSeptember 20, 20246:53 PM UTCUpdated ago
Text
Small Text
... |
| Sep 18, 2024 | Patents for software and genetic code could be revived by two bills in Congress | Enlarge / An image from the U.S. Patent and Trademark Office, where in 1874, the newest thing was not software or genetic compositions, but shutter fastenings from H.L. Norton.
Andrew Harrer/Bloomberg via Getty Images reader comments 96
The... |
| Aug 16, 2024 | National Politics | Biggest lobbying interests buck trend with higher 2024 spending | “Election years bring some trepidation for the lobbying business because of the uncertainty about the legislative outlook and political outlook, but interest is heightened beyond belief right now,” said William Moschella, co-chair of the go... |
| Jul 23, 2024 | Health | Angry patients spur new state watchdogs to bring down drug prices | “Drug pricing is an extremely complex system, and you need experts in the space that understand how everything works,” said Andrew York, executive director of Maryland’s Prescription Drug Affordability Board. “Every state is proposing diffe... |
| Jun 11, 2024 | Health | An obscure drug discount program stifles use of federal lifeline by rural hospitals | Federal lawmakers have introduced a handful of legislative solutions since March. In one bill, senators from Kansas and Minnesota list a myriad of tactics, including allowing older closed facilities to reopen.
Another proposal introduced in... |
| Jun 5, 2024 | 340B reform efforts pick up steam | figcaption>span]:font-sans">
Momentum is building on both sides of the Capitol to make comprehensive changes to the federal 340B drug discount program — though it's unclear how much money the plans would save.
Why it matters: Sur... |
| May 21, 2024 | Senate Judiciary presses for drug patent reforms | figcaption>span]:font-sans">
Senate Judiciary Committee members today used a hearing on drug patents to take shots at drugmakers and PBMs while bemoaning the slow process for bringing legislation to the floor.
Why it matters: The... |
| May 20, 2024 | Senate's new controversial patent reform target | figcaption>span]:font-sans">
Sens. Chris Coons and Thom Tillis are pushing a pair of bills that they say are essential to overhauling the patent process, including for drugs and genomics, but that critics contend could wind up he... |
| May 9, 2024 | Axios Pro tracker: Health care bills to watch | figcaption>span]:font-sans">
Data: Axios Research; Chart: Rahul Mukherjee/Axios
We're trying out something new: a handy cheat sheet for some of the big-ticket policy items that could find a home in must-pass legislation.
Why it m... |
| Mar 22, 2024 | Years later, states' drug pricing boards have yet to bring down costs | Five years after the creation of the first state board empowered to cap prescription drug costs, patients still haven't seen any savings from these efforts.
Why it matters: Even as more blue and purple states embrace public drug pricing boa... |
| Mar 18, 2024 | Pandemic pact crunch time: Final treaty talks start to prevent future deaths | An international draft treaty aimed at bolstering readiness for the next pandemic enters a final round of scheduled negotiations Monday, with key disagreements remaining about how much knowledge and product drugmakers must share with the wo... |
| Mar 13, 2024 | Pharma dealt a loss over drug discount program | Pharmaceutical interests lost a closely watched battle over the federal drug discount program on Tuesday when a federal appeals court ruled that Arkansas can block manufacturers from limiting the availability of discounted drugs at certain ... |
| Mar 6, 2024 | Agatha Co., Ltd. “Agatha”, a document management cloud service for clinical trials and clinical research, develops a new function that streamlines clinical trial procedures using Japan’s first generative AI | [Agatha Co., Ltd.] “Agatha”, a document management cloud service for clinical trials and clinical research, develops a new function that streamlines clinical trial procedures using Japan’s first generative AI
*View in browser* *Agatha Co., ... |
| Mar 6, 2024 | Agatha Co., Ltd. “Agatha”, a document management cloud service for clinical trials and clinical research, develops a new function that streamlines clinical trial procedures using Japan’s first generative AI | |
| Nov 24, 2023 | Health | Biden administration’s limit on drug industry middlemen backfires, pharmacists say | Arthur Allen | (TNS) KFF Health News
The Biden administration’s first major step toward imposing limits on the pharmacy benefit managers who act as the drug industry’s price negotiators is backfiring, pharmacists say. Instead, it’s adding t... |
| Aug 20, 2023 | Why OneOncology Is Adopting Verily’s Clinical Trial Management System | More than 1,300 oncology drugs are in the development pipeline, waiting to potentially embark on the long journey toward their commercial debut. This journey is usually an arduous one, made even more difficult by the mere 6% participation r... |
| Aug 11, 2023 | Federal drug discount program faces renewed scrutiny | A federal drug discount program for safety-net providers that's been a perennial source of fierce disputes among health care industry powerhouses is back in the spotlight, with billions of dollars at stake.
The big picture: Separate but coi... |
| Jul 6, 2023 | Biden promised a ‘war on cancer’ — but declared war on the cure instead | When then-Vice President Biden launched the Cancer Moonshot in 2016, there was reason to be optimistic. Decades of rigorous science had transformed many cancers from a death sentence to a manageable chronic disease. New treatment advances —... |
| Jun 22, 2023 | Pharmaceutical lobbyists challenge Biden's drug law in friendly territory | The top lobbying organization for the pharmaceutical industry yesterday filed the fourth lawsuit challenging Democrats' law that gives Medicare the power to negotiate the prices of certain drugs, this time in a Texas district court.
Why it ... |
| Jun 21, 2023 | PhRMA sues over Medicare drug pricing provisions | Pharmaceutical Research and Manufacturers of America announced Wednesday it is suing the Biden administration over its signature measure to lower drug prices, calling it unconstitutional.
Why it matters: The move is an escalation in the pha... |
| Jun 13, 2023 | 70% Of Major Pharmaceutical Companies And CROs Surveyed Have Adopted Digital Pathology | "The results of the 2023 Life Sciences Digital Pathology Adoption Survey confirms that digital pathology has earned its place on the C-suite agenda across life sciences organizations,” said David West, Proscia’s CEO
PHILADELPHIA (PRWEB... |
| May 16, 2023 | How AI Can Deliver Benefits in Healthcare Manufacturing and Patient Device Usage | According to Grand View Research, the global artificial intelligence (AI) in healthcare market size was valued at USD 15.4 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 37.5% from 2023 to 2030, to reach ... |
| Apr 24, 2023 | Virscio Deploys Proscia’s Software To Improve Efficiency Of Drug Research And Development | Virscio is leveraging Concentriq for Research to unify its teams and pathology data across GLP and non-regulated preclinical studies. “Translating concept to clinical success requires innovative technology, and we’ve found this in Concentri... |
| Mar 21, 2023 | Altasciences Selects Proscia To Accelerate The Development Of Life-Saving Drugs | “Our decision to adopt digital pathology and chart our course with Proscia strongly reflects Altasciences’ guiding focus on ensuring our sponsors’ success,” said Dr. Wendell P. Davis, Vice President of Pathology.
LAVAL, Québec and PHILADELP... |
| Feb 14, 2023 | Doing More with Moore: Biotech’s Tech Moment | Eroom’s Law (the backwards Moore) is the often cited, and arguably inaccurate, observation that drug discovery gets slower and more expensive over time. It’s certainly a slog, but R&D efforts have yielded 378 new FDA-approved drugs betw... |
| Jan 20, 2023 | Even with lawsuits and copay caps, will insulin ever be affordable? | In an attempt to tackle the root causes of inflated insulin prices, the state of California filed a lawsuit last week accusing drug manufacturers and pharmacy benefit managers of artificially and illegally jacking up the price of insulin.
T... |
| Jan 5, 2023 | MPA & RIAA Deployed 60+ Lobbyists in 2022, Piracy Top of The Agenda | A quote attributed to former UK Prime Minister Winston Churchill suggests that democracy is actually the worst form of government – except for all the others.
It’s a depressing take on the political gold standard, but the full quote adds mo... |
| Dec 14, 2022 | States challenge Biden to lower drug prices by allowing imports from Canada | The Biden administration is facing mounting pressure from states to let them import medicine from Canada to help lower prescription drug costs.
Colorado on Dec. 5 became at least the fourth state to seek federal permission to use the strate... |
| Dec 14, 2022 | To protect the medical supply chain, ‘made in America’ will be key | The Covid-19 pandemic exposed a serious flaw in the United States’ medical supply chain: an overreliance on imported supplies. Reinvigorating a domestic supply chain is an important step toward protecting Americans’ health and the country’s... |
| Aug 17, 2022 | Inflation Reduction Act could be "game-changing" for millions of U.S. seniors | The Inflation Reduction Act (IRA) that President Biden signed into law Tuesday represents the most important effort in decades to reform how drug prices are set in the U.S. — the nation that spends more per capita on medicine than any other... |
| Jul 19, 2022 | Following Luxturna and slate of eye disease approvals, Roche adds another ophthalmology partner for AAV gene therapies | While PhRMA is engaged in a fierce battle on Capitol Hill over new Medicare drug price negotiations, which the top pharma industry lobby argues will take a big cut on innovation, the group also unveiled a new report finding its member compa... |
| Jun 8, 2022 | FDA user fee legislation needs to mitigate the pharmaceutical industry’s carbon pollution | As Congress works to reauthorize for the seventh time pharmaceutical user fee legislation, it is overlooking what should be part of virtually every law that affects industry these days: the climate crisis.
The Prescription Drug User Fee Act... |
| Apr 8, 2022 | Viatris doubles down on Sesame Workshop collaboration, kicking in another $1M | As experts speculate that Covid-19 could soon shift to an endemic stage, Viatris is once again turning to everyone’s favorite Muppets for its latest pandemic relief contribution.
Lara Ramsburg
The healthcare company — ... |
| Feb 11, 2022 | With sotrovimab in the balance, Biogen vet reunites with George Scangos at Vir; First woman to chair PhRMA has more in store at Takeda | Johanna Friedl-Naderer
Vir Biotechnology is getting another Biogen vet to join up as the startup’s new global CBO and EVP.
While Johanna Friedl-Naderer officially doesn’t start her first C-suite role for another few weeks on March 2, she wi... |
| Dec 16, 2021 | Why the big questions about drug prices are rarely asked: It’s hard to do | Public debate over legislation to allow Medicare to negotiate the price of drugs has been dominated by stories of personal suffering caused by high drug prices, accounts of lifesaving cures provided by pharmaceutical innovations, and argume... |
| Nov 11, 2021 | Drug Price Negotiation Is A Second-Best Fix. Here's What Will Really Work | As Democrats struggle to bring together 50 votes to pass the Build Back Better Act, a major sticking point with the legislation has emerged. That is, whether it should include provisions changing the law to allow Medicare to negotiate drug ... |
| Nov 3, 2021 | Medicare drug price negotiation provision could avoid concerns about stifling innovation | The proposal to allow Medicare to negotiate with pharmaceutical companies over drug prices is structured in a way intended to preserve the industry’s ability to pursue new drugs. Industry groups have long said that such negotiations would w... |
| Oct 25, 2021 | NantHealth : Helping Payers and Providers Navigate the Perfect Storm to Drive Better Outcomes | The burden of cancer and autoimmune diseases is heavy on patients, providers, and payers in the United States. Nearly 40 percent of men and women will be diagnosed with cancer at some point during their lifetimes. It's one of the leading ca... |
| Oct 1, 2021 | Atlas creates second opportunity fund with $300M; BioNTech's colorectal cancer vaccine starts PhII trial | Life science VC Atlas Venture closed its second Opportunity Fund with $300 million. Known as AVOF II, the fund will enable Atlas to continue backing its portfolio companies, according to a company statement.
“We are d... |
| Sep 15, 2021 | Congress is about to legislate a future without new medicines. We have a better plan | One of the fundamental principles on which the U.S. economy is based is that the expectation of a positive return drives one’s willingness to invest time and money. Individuals investing in a portfolio of stocks hope that some stocks’ gains... |
| Jul 30, 2021 | Alzamend Neuro : Annual Report (SEC Filing - 10-K) | UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended April 30, 2021
Commission file number 001-40483... |
| Apr 29, 2021 | New PhRMA Report Shows Nearly 90 Medicines in Development to Fight Drug-Resistant Infections, but Future Pipeline Remains Challenging | |
| Mar 25, 2021 | The “biggest thorn in President Trump’s side” is now HHS Secretary. What’s next? | Yet, despite his lack of medical background, Becerra has years of experience drafting and defending laws to protect the public’s health.
“We found it impressive that he was unafraid to go against big and powerful industry players, whether d... |
| Mar 10, 2021 | All That Glitters Isn't Gold: Questions To Ask Yourself Before Investing In Biotech | Senior life science commerical strategy consultant and Managing Partner at Red Team Associates |
| Mar 9, 2021 | Merck inks Keytruda deal with Surface Oncology; Rocket Pharmaceuticals gets expedited review of gene therapy for rare pediatric disease | Merck’s cash cow Keytruda has found another partner.
The pharma took the wraps off a collaboration deal on Tuesday to pair Keytruda with Surface Oncology’s IL-27 targeting antibody SRF388. The combo will be studied as ... |
| Feb 4, 2021 | Hospital Practices Increase Costs of Medicines for Patients & Employers, New Report Shows | |
| Feb 4, 2021 | Ramona Sequeira to become PhRMA's first female chair; McKinsey reaches nearly $574 million settlement over involvement in opioid crisis | PhRMA is getting its first female board chair.
On Thursday, the trade association celebrated news that Ramona Sequeira, president of Takeda’s US business, has been named chair-elect. The former board treasurer is set to s... |
| Jan 2, 2021 | Court Injunction Temporarily Upends Most Favored Nation Policy To Lower Prices Of Medicare Part B Drugs | U.S. President Donald Trump speaks during an executive order signing ceremony on lowering drug ... [+] prices in the Eisenhower Executive Office Building in Washington, D.C., U.S., on Friday, July 24, 2020. Trump announced new policies aime... |
| Dec 16, 2020 | Contract Logix Helps Biotech and Pharmaceutical Industries Accelerate Innovation and Commercialization | Data-Driven Contract Management Software The pharmaceutical industry is undergoing a rapid and dynamic transformation, and it needs business tools that can keep pace. Taking a data-driven approach to contract management is essential for suc... |
| Dec 15, 2020 | Report: More than 1,300 Medicines and Vaccines in Development to Help Fight Cancer | |
| Dec 9, 2020 | Sen. David Perdue is raising big campaign money with DC lobbyists. He also traded stock shares of several of the companies the lobbyists represent. | Republican Sen. David Perdue of Georgia has faced federal scrutiny for his many stock trades. He maintains he's done nothing wrong as he seeks a second term ahead of a January runoff vote. Chip Somodevilla/Getty Images
Georgia GOP Sen. Davi... |
| Dec 1, 2020 | The U.S. must support access to care and incentives for the innovation that transforms it | The deadly spread of Covid-19 around the world has highlighted the importance of innovation and cooperation between the various actors in the U.S. health care system. It has shown what can be achieved in an environment that rewards innovati... |
| Oct 5, 2020 | The U.S. needs to support American-made medicines | Two years ago, a group of U.S. hospitals launched Civica Rx, a nonprofit generic drug company that I have the honor to lead. Its core mission is to deliver quality medicines at sustainable prices.
From the very start, part of Civica’s appro... |
| Sep 19, 2020 | Pricing deal collapses over Big Pharma's refusal to issue $100 'cash cards' before the election — report | Late in August, as negotiations on a pricing deal with President Trump reached a boiling point, PhRMA president Stephen Ubl sent an email update to the 34 biopharma chiefs that sit on his board. He wrote that if the industry... |
| Sep 14, 2020 | Trump ups the stakes with 'granddaddy of them all' drug pricing executive order. But he could be running out of time | When President Donald Trump signed four executive orders in late July aiming at lowering drug prices, details of the most controversial — “the granddaddy of them all,” according to Trump — were conspicuously missing.... |
| Jul 23, 2020 | THRYV HOLDINGS, INC.
Thryv : Mid-year Review Of 2020's Major Patent Cases From Across The Globe | Without a question or a doubt, 2020 is a year like none other the world has seen. The impacts of coronavirus have prompted a world economic shutdown on an unprecedented scale. In the legal industry, courts have struggled to adjust to the ne... |
| Dec 10, 2019 | Do large pharma companies provide drug development innovation? Our analysis says no | Large pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medic... |
| Oct 17, 2019 | Pelosi’s drug pricing plan puts medical innovation at risk | The future of medical innovation in America is at a crossroads.
Biopharmaceutical science is accelerating at a record pace, leading to new discoveries that are radically reshaping our ability to fight disease. At the same time, politicians ... |
| Oct 4, 2019 | Atlas-backed Dyne taps Joshua Brumm as CEO; Sekar Kathiresan woos cardiologist to gene editing startup | → Romesh Subramanian’s new biotech startup, Dyne Therapeutics, which is using oligonucleotides to degrade RNA responsible for disease has brought on Joshua Brumm as president and CEO. Subramanian will now take on the CSO... |
| Oct 2, 2019 | Trade agreement drug monopoly is obsolete given faster, better drug discovery | For decades, the brand-name drug industry has relentlessly promoted the message that any reduction in its government-protected monopolies would have detrimental effects on innovation. Members of Congress on both sides of the aisle have take... |
| Jul 10, 2019 | Pharmaceutical mergers and megamergers stifle innovation | It isn’t lost on the public that the pharmaceutical industry is putting profits over people. Over 80% of Americans across party lines believe that lowering drug costs should be a “top priority” for lawmakers. Policymakers across the politic... |
| May 8, 2019 | HHS implements rule to require list prices in television drug ads | “We believe today’s step on transparency will help make prices in healthcare work much more like they in any other market—not utterly uniform, but more predictable and more competitive,” HHS Secretary Alex Azar said in prepared remarks Wedn... |
| Oct 26, 2018 | Trump calls Medicare Part B proposal ‘revolutionary,’ but experts see limited benefits | In response, the administration is proposing that Medicare Part B would use reference pricing, allowing Medicare to determine what it pays based on what other countries pay.
However, Howard Deutsch, principal at management consulting firm Z... |
| Oct 15, 2018 | Drugmakers propose pricing information in DTC ads, but Trump administration says it’s not enough | Inclusion of list prices in DTC advertising – in particular calling on the Food and Drug Administration to evaluate their inclusion in ads – is among the proposals for tackling high drug prices in the Trump administration’s “American Patien... |
| Sep 18, 2018 | Lawmakers halt push for drug prices in TV ads | In an effort to get the first set of FY 2019 appropriations bills to the President’s desk, US House leaders scrapped a bipartisan amendment that would have required drugmakers to include list prices in direct-to-consumer (... |
| Sep 7, 2018 | Rush to end drug rebates may be bad for patients, payers, and pharma | In health care circles, 21 words have rarely caused as much speculation as “Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection,” the title of prop... |
| Aug 22, 2018 | CVS move points to growing interest in value-based drug pricing | The way drugs are priced does appear headed in the direction of emphasizing value, said Robin Feldman, professor of law and the University of California Hastings in San Francisco. “I think value-based pricing is on the horizon – I believe w... |
| May 30, 2018 | PhRMA's new report counts each cancer drug in the US pipeline, which has now swelled to over 1,000 in the clinic | Cancer drugs are crowding in to an already cramped pipeline this year, with hundreds of immuno-oncology hopefuls now taking a shot at clinical testing. That’s according to a new cancer report from PhRMA, which counted 1,12... |
| Jan 31, 2018 | After 18 years, will vTv Therapeutics’ Alzheimer’s drug sink or swim? | It would be the first new therapy the field has seen in 15 years, sweeping into a market projected to be worth $11.3 billion by 2021. But there’s no guarantee that the drug won’t stumble at the line. It’s high risk, high reward to say the l... |
| Dec 19, 2017 | Facing showdown on high drug prices, industry group PhRMA revenue surges to highest level in 7 years | “Does that surprise you?” said Billy Tauzin, the former PhRMA CEO who ran the organization a decade ago as Obamacare loomed. Whenever Washington seems interested in limiting drug prices, he said, “PhRMA has always responded by increasing it... |
| Nov 20, 2017 | Is it time to say goodbye to ClinicalTrials.Gov? | With the explosion of clinical trials, the need to recruit patients has grown exponentially but the patient population willing to participate in trials has not grown nearly as much. Not only are a lot more patients needed, but also it has b... |
| Oct 13, 2017 | Biotech entrepreneur Saurabh Saha moves to translational research chief at Bristol-Myers; Ex-GSK pharma chief Hussain switches to private equity | Saurabh Saha
→ Bristol-Myers Squibb $BMY has hired Saurabh Saha to run their translation science group, which is responsible for triaging preclinical work of interest and steering the most promising programs toward the c... |
